Comparative Pharmacology
Head-to-head clinical analysis: KRINTAFEL versus PRIMAQUINE PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KRINTAFEL versus PRIMAQUINE PHOSPHATE.
KRINTAFEL vs PRIMAQUINE PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KRINTAFEL (tafenoquine) is an 8-aminoquinoline antimalarial that inhibits parasite growth by interfering with the electron transport chain in the mitochondria of Plasmodium species. It is active against both the erythrocytic and exoerythrocytic stages, including hypnozoites of P. vivax.
Primaquine is a 8-aminoquinoline antimalarial agent that disrupts the mitochondrial function of malarial parasites. It is active against hypnozoites of Plasmodium vivax and P. ovale, and gametocytes of P. falciparum. The exact mechanism is thought to involve the generation of reactive oxygen species through redox cycling, leading to parasite death.
Adults: 200 mg orally as a single dose.
Adults: 30 mg (base) orally once daily for 14 days for radical cure of Plasmodium vivax and P. ovale; 15 mg (base) orally once daily for 14 days for prevention of relapse in mild cases. For prophylaxis: 30 mg (base) orally once daily beginning 1 day before travel, continued daily during travel, and for 7 days after leaving endemic area (alternative to chloroquine). Administer with food.
None Documented
None Documented
Terminal elimination half-life is approximately 5-7 days in healthy subjects. Due to accumulation, steady state is achieved after 4-5 weeks of weekly dosing. In patients with renal impairment, half-life may be prolonged.
Terminal elimination half-life ranges from 4 to 6 hours in healthy adults; may be prolonged in renal impairment. Clinical context: due to short half-life, daily dosing is required; accumulation of active metabolites may contribute to efficacy.
Primarily renal; approximately 70-80% of administered dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Fecal excretion accounts for less than 5%.
Renal: approximately 1% unchanged; major metabolites (e.g., carboxyprimaquine) are excreted renally. Fecal/biliary: minor route (less than 5%). Total renal elimination of parent drug and metabolites accounts for about 60-70% of a dose.
Category C
Category D/X
Antimalarial
Antimalarial